Go To Global Site
Welcome to UCB in the United States

Dec

02

Working Toward a More Equitable Future: Addressing Barriers in the Hispanic Epilepsy Community

To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.

Nov

30

FDA Approves Shelf Life Extension for NAYZILAM® (midazolam) Nasal Spray, CIV

The U.S. Food and Drug Administration has reviewed new drug stability data and approved a shelf life extension from 12 to 24 months for NAYZILAM® (midazolam) nasal spray, CIV. NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.1

Nov

29

Advancing Our Mission to Cure Epilepsy

With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Nov

11

Mission-driven, Patient-focused: How Healthcare Gave Me a Second Chance to Serve

During my time in the Navy, I developed a strong sense of purpose, service and mission. After fulfilling my service obligation, I was eager to find another career that continued to allow me to do something larger than myself. I found at UCB, a company that makes medicines to help improve the lives of people living with epilepsy, a different type of service: service to patients.

Nov

08

Epilepsy & Caregiving: A Caregiver’s Perspective on the Role of Telehealth

UCB spoke with caregiver, Debbie, about her experience caring for her daughter living with epilepsy and its personal impact on her, as well as the important role of telehealth in epilepsy care. Her story speaks to the challenges many caregivers face when looking after their loved ones and the importance of prioritizing their own mental health. As one of UCB’s Epilepsy Advocates and as a patient advocate for the Epilepsy Foundation, Debbie supports others living with epilepsy and their families throughout their healthcare journey. In these roles, she helps many find access to the right mental health resources, which she says can be a “game changer” for both epilepsy patients and their loved ones.

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Nov

03

Improving the Patient Journey in Rheumatology

UCB is excited to exchange ideas at ACR Convergence, Nov. 3-9, 2021. Learn more about our presence at the conference and work in rheumatology from Dr. Jeffrey Stark, Head of Immunology Medical Affairs U.S.

Nov

03

Epilepsy & Mental Health: A Patient’s New Outlook on Life

UCB spoke with Tim, who has been living with epilepsy since 1979 while he was on active duty. His story focuses on the challenges that epilepsy brings but also shares how his new, positive outlook on life has changed the way he lives. As a member of UCB’s Epilepsy Advocate program, Tim helps to support other epilepsy patients and has been a resource for others during their journey with epilepsy.

Nov

01

Voices on Value: The importance of patient-focused value assessment, Part 2

As innovators in the healthcare industry, UCB and The Innovation and Value Initiative (IVI) believe recognizing patient voices in value assessments is important. In our recent Voices on Values series, our Head of U.S. HEOR Strategy, Edward Lee, sat down with Jennifer Bright, Executive Director at IVI to discuss how we can ensure all patient voices are captured in value assessments. Learn more about their conversation.